Longeveron granted U.S. patent for method of treating female sexual dysfunction

Longeveron (LGVN) announced that the United States Patent and Trademark Office has granted a patent covering administration of the Company’s proprietary mesenchymal stem cells for the treatment of female patients with sexual dysfunction and improvement in sexual quality of life. U.S. Patent No. 12,496,316, entitled “Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.